Business
Gb Sciences to Present at the SNN Network Summer Virtual Event on Wednesday, August 18th, 2021
Gb Sciences to Present at the SNN Network Summer Virtual Event on Wednesday, August 18th, 2021.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"LAS VEGAS, NV / ACCESSWIRE / August 10, 2021 / Gb Sciences (OTCQB:GBLX), a plant-based research and biopharmaceutical drug development company, today announced that it will be presenting at the SNN Network Summer Virtual Event 2021 on Wednesday, August 18th at 3:00 PM EST. Dr. Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences will be hosting the presentation and answering questions from investors.To access the live presentation, please use the following information:SNN Network Summer Virtual Event 2021Date: Wednesday, August 18, 2021Time: 3PM Eastern Time (12PM Pacific Time)Webcast: https://www.webcaster4.com/Webcast/Page/2750/42235Dr. Andrea Small-Howard will be sharing in her presentation more details about GB Sciences' recent pivot from a cannabis-based company to a biotech."We're now going all-in on Cannabis-based products that are destined to go through FDA regulated pathways to provide help to the largest number of people."If you would like to book 1on1 investor meetings with Gb Sciences, and to watch Gb Sciences' presentation, please make sure you are registered for the virtual event here: https://conference.snn.network/signup1on1 meetings will be scheduled and conducted via private, secure video conference through the conference event platform.The SNN Network Summer Virtual Event website is available here: https://conference.snn.network/If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda": https://conference.snn.network/agendaNews Compliments of AccesswireAbout Gb Sciences, Inc.Gb Sciences, Inc. (OTCQB:GBLX) is a plant-based research and biopharmaceutical drug development company whose goal is to create patented formulations of plant-inspired, optimized therapeutic mixtures (OTM) that target a variety of medical conditions through their Canadian entity, GbS Global Biopharma, Inc. The ‘plant-inspired' active ingredients in our OTM are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices (cGMP). Gb Sciences' novel drug discovery platform has yielded 5 issued US and 3 issued international patents, as well as 19 US and 40 international patent-pending applications. In our dr...